Neuropilin-1 Controls Endothelial Homeostasis by Regulating Mitochondrial Function and Iron-Dependent Oxidative Stress

HIGHLIGHTS
- A subcellular pool of NRP1 localizes in the mitochondria of endothelial cells (ECs).
- NRP1 regulates mitochondrial function via ABCB8 transporter.
- NRP1 loss induces iron accumulation and iron-dependent oxidative stress in ECs.
- NRP1 protects ECs from iron-dependent premature cellular senescence.

Issitt et al., iScience 11, 205–223 January 25, 2019 © 2018 The Author(s).
https://doi.org/10.1016/j.isci.2018.12.005
Neuropilin-1 Controls Endothelial Homeostasis by Regulating Mitochondrial Function and Iron-Dependent Oxidative Stress

Theo Issitt,1,5 Emy Bosseboeuf,1,5 Natasha De Winter,1 Neil Dufton,1 Gaia Gestri,2 Valentina Senatore,3 Anissa Chikh,4 Anna M. Randi,1 and Claudio Raimondi1,6,*

SUMMARY

The transmembrane protein neuropilin-1 (NRP1) promotes vascular endothelial growth factor (VEGF) and extracellular matrix signaling in endothelial cells (ECs). Although it is established that NRP1 is essential for angiogenesis, little is known about its role in EC homeostasis. Here, we report that NRP1 promotes mitochondrial function in ECs by preventing iron accumulation and iron-induced oxidative stress through a VEGF-independent mechanism in non-angiogenic ECs. Furthermore, NRP1-deficient ECs have reduced growth and show the hallmarks of cellular senescence. We show that a subcellular pool of NRP1 localizes in mitochondria and interacts with the mitochondrial transporter ATP-binding cassette B8 (ABCB8). NRP1 loss reduces ABCB8 levels, resulting in iron accumulation, iron-induced mitochondrial superoxide production, and iron-dependent EC senescence. Treatment of NRP1-deficient ECs with the mitochondria-targeted antioxidant compound mitoTEMPO or with the iron chelator deferoxamine restores mitochondrial activity, inhibits superoxide production, and protects from cellular senescence. This finding identifies an unexpected role of NRP1 in EC homeostasis.

INTRODUCTION

Neuropilin-1 (NRP1) is a transmembrane protein expressed by many cell types including endothelial cells (ECs) (Raimondi et al., 2016). Ablation of NRP1 expression in mice results in embryonic lethality caused by severe neural and vascular defects (Kawasaki et al., 1999; Kitsukawa et al., 1997). NRP1-dependent signaling pathways in ECs are essential for vascular development because endothelial-specific NRP1 knockout mice recapitulate the vascular defects of the global NPR1 knockout (Gu et al., 2003). ECs line the inner surface of blood vessels forming a quiescent selectively permeable monolayer and proliferate rarely over months or years (Augustin, 2004). In contrast, ECs proliferate and migrate in response to proangiogenic factors such as vascular endothelial growth factor (VEGF-A) during angiogenesis. NRP1 has been mainly investigated as a co-receptor for VEGF-A, but recent evidence shows that NRP1 also regulates VEGF-independent extracellular-matrix-mediated pathways that promote physiological and pathological angiogenesis (Fantin et al., 2015; Raimondi et al., 2014, 2015). Although the role of NRP1 in angiogenesis is well understood, the contribution of NRP1 signaling in the adult quiescent vasculature is less defined. The maintenance of endothelial homeostatic function over time is critical to prevent excessive permeability, thrombosis, and inflammation (Rajendran et al., 2013; Sena et al., 2013). In the adult vasculature, NRP1 has been implicated in VEGF-induced vascular permeability (Acevedo et al., 2008; Becker et al., 2005; Fantin et al., 2017; Raimondi et al., 2016, Roth et al., 2016) and in vascular leakage in a mouse model of diabetic retinal injury (Wang et al., 2015), but whether NRP1 has a broader role in EC homeostasis is poorly understood.

Mitochondria are emerging as regulators of EC signaling and function. ECs rely mainly on anaerobic glycolysis to meet their energy demand and to produce ATP (De Bock et al., 2013); thus mitochondrial contribution to EC energy production is limited in physiological conditions. However, mitochondria are essential for EC function because altering mitochondrial dynamics induces endothelial dysfunction (Shenouda et al., 2011). Accordingly, mitochondria regulate shear stress-induced vasodilation, hypoxia signaling, autophagy, and pro-inflammatory activation by producing mitochondrial reactive oxygen species (ROS), which act as a signaling molecule (Al-Mehdi et al., 2012; Liu et al., 2008). Conversely, fragmentation of the mitochondrial network occurs in ECs following exposure to oxidative stress (Jendrach et al., 2008), high glucose...
Mitochondria are also a focal point for the regulation of cellular redox potential and iron metabolism. Mitochondria synthesize the iron-sulfur protein (Fe/S) clusters, which are essential for the electron transfer reactions and produce the heme’s precursor compound protoporphyrin IX (Beinert et al., 1997; Hamza and Dailey, 2012; Lill et al., 1999). Thus mitochondria require iron to function and play a central role in iron metabolism. Defects in mitochondria biogenesis and morphology contribute to endothelial dysfunction and to the pathogenesis of cardiovascular diseases (Ong et al., 2010; Shenouda et al., 2011). Accordingly, the extent of atherosclerosis correlates with mitochondrial DNA damage in patients and in atherosclerosis mouse models (Ballinger et al., 2002). Furthermore, depletion of mitochondrial biogenesis regulator peroxisome proliferator-activated receptor γ coactivator 1α results in vascular dysfunction and inflammation because of increased mitochondrial ROS production in response to chronic angiotensin II infusion (Kroller-Schon et al., 2013).

ROS are mainly generated as a by-product of the mitochondria electron transport chain during oxidative phosphorylation (Turrens, 2003) or by accumulation of transition metals such as iron. Accumulation of iron induces the formation of redox-active iron pools able to catalyze the production of free radical via Fenton chemistry (Kell, 2009; Silva-Gomes et al., 2014). ECs are equipped to withstand mechanical and chemical stresses and to maintain their function despite the physiological increases of cytokines, chemokines, and ROS during inflammation or infection. However, recent evidence shows that prolonged sustained ROS levels contribute to endothelial dysfunction and to the inflammatory response in atherosclerosis and coronary heart diseases (Cai and Harrison, 2000; Forstermann, 2008; Panth et al., 2016). Furthermore, elevated ROS levels induce premature EC senescence, which impairs EC function and homeostasis. In the aging cardiovascular, senescent ECs accumulate in atherosclerotic lesions and likely contribute to disease progression by creating a pro-inflammatory and pro-thrombotic environment (Minamino et al., 2002; Vasile et al., 2001; Warboys et al., 2014).

Senescent cells irreversibly lose the ability to replicate and thereby contribute to tissue aging by disrupting tissue homeostasis (van Deursen, 2014). Replicative cell senescence is usually caused by progressive telomere shortening at each round of cell duplication (Cristofalo et al., 2004; Shay and Wright, 2005). In addition, DNA damage, oxidative stress, or mitochondrial dysfunction can cause premature senescence by telomere-independent mechanisms (Erusalimsky, 2009). EC senescence impairs vascular functions such as angiogenesis, nutrient trafficking, and vascular repair because it decreases proliferation and migration of ECs (Foreman and Tang, 2003).

Here, we found that in addition to the well-established role in angiogenesis, NRP1 also has a role in EC health in non-angiogenic conditions by promoting mitochondrial function through the mitochondria-specific ATP-binding cassette transporter ABCB8 (Ichikawa et al., 2012, 2014). Downregulation of NRP1 increases iron levels in ECs and induces iron-dependent oxidative stress, which results in mitochondrial superoxide production, decreased mitochondrial activity, and EC senescence. As iron chelation restored mitochondrial activity, reduced mitochondrial superoxide, and reduced EC senescence in NRP1-deficient ECs, our findings indicate that NRP1 protects ECs from mitochondrial damage by reducing iron-dependent oxidative stress and thereby decreases premature EC senescence.

RESULTS

NRP1 Localizes in the Mitochondria and Controls Mitochondrial Morphology in ECs Independently of VEGFR2

To investigate a potential role of NRP1 in mitochondria, we first investigated whether NRP1 localizes in the mitochondria of human microvascular endothelial cells (HDMECs) by performing immunostaining for NRP1 and the mitochondrial outer membrane component TOM20. Specificity of anti-NRP1 antibody was confirmed by staining HDMECs downregulated for NRP1 expression using a previously validated small interfering RNA (siRNA) (Fantin et al., 2015, 2017; Raimondi et al., 2014)(Figures S1A and S1B). As expected, NRP1 was distributed throughout the cytoplasm and was enriched at the plasma membrane and in filopodia (Figure S1A). Co-localization analysis of de-convoluted high-magnification z stack, which generated pseudo-colored “product of the differences from the mean” (PDM) images in which each pixel is equal...
to the PDM value, showed that NRP1 co-localizes with TOM20 in the mitochondria (Figures 1A, S1C, S1C and S1D). We further investigated whether NRP1 is in close proximity with TOM20 by performing proximity ligation assay (PLA), which generates a fluorescent signal when target proteins are within a distance of 40 nm. Interestingly, HDMEC si-control showed a positive PLA signal, which was significantly decreased in HDMEC si-NRP1 (Figures S1E and S1F), suggesting that NRP1 localizes in the mitochondria. To confirm this finding, we performed mitochondrial fractionation. Cytoplasmic and mitochondrial fractions of HDMECs were immunoblotted for the cytoplasmic marker GAPDH and for the mitochondrial inner and outer membranes markers ABCB8 and TOM20, respectively (Figure 1B). Furthermore, fractions were immunoblotted for the endoplasmic reticulum (ER) marker KDEL and for the endosome marker EEA1 (Figure S1G). Importantly, the mitochondrial fraction was negative for cytoplasmic, endosomal, and ER markers, indicating that the mitochondrial fractions isolated were pure. Strikingly, NRP1 was detected by immunoblotting in the mitochondrial fraction (Figures 1B and S1G) as well as in the cytoplasmic fraction and in the whole lysate. Together these data show that a subcellular pool of NRP1 localizes into the mitochondria.

To determine whether NRP1 or VEGF signaling plays a role in mitochondrial function, we downregulated NRP1 or VEGFR2 expression in HDMECs and investigated mitochondrial morphology. Thus we analyzed the mitochondrial network coverage in HDMECs transfected with NRP1 targeting, VEGFR2-targeting, or with control siRNA (Figures 1C and 1D). Mitochondria were live stained with MitoTracker, and mitochondrial network area and volume were quantified by generating a 3D-rendered surface built on the MitoTracker fluorescence from optical z stacks acquired through high-resolution confocal microscopy (Figure 1E). Quantification revealed that NRP1-deficient, but not VEGFR2-deficient, HDMECs have reduced mitochondrial area and volume compared with control cells, suggesting that NRP1 regulates the extent of mitochondrial network independently of VEGF signaling (Figure 1F).

Then, we analyzed the protein level of the mitochondrial mass indicator TOM20 by immunoblotting, as a measurement of mitochondrial content (Burbulla et al., 2014). In agreement with the reduced mitochondrial network coverage (Figures 1E and 1F), NRP1 downregulation in HDMECs significantly reduced TOM20 levels compared with control cells, suggesting a decrease in mitochondrial mass in NRP1-deficient HDMECs (Figures 1G and 1H).

Because mitochondria are organized in a network maintained by organelle fission and fusion (Chan, 2006), we investigated whether NRP1 downregulation affects the expression of mitofusin-1 (MFN1) and mitofusin-2 (MFN2), which are known to promote mitochondrial fusion (Lugus et al., 2011; Ong et al., 2010). In agreement with the reduced mitochondrial network observed above (Figures 1E and 1F), we found
that NRP1 downregulation significantly decreases MFN1, but not MFN2 expression (Figures 1I and 1J). Together, these data show that a pool of NRP1 localizes in the mitochondria and that NRP1 regulates mitochondrial mass and the organization of the mitochondrial network in ECs.

**NRP1 Protects Mitochondrial Activity and Prevents Oxidative Stress in ECs**

Because NRP1 loss reduces mitochondrial mass and mitochondrial network coverage, we investigated whether NRP1 promotes mitochondrial activity. In aerobic conditions, NADH and FADH$_2$ produced during glycolysis, β-oxidation, and other catabolic processes are oxidized using molecular oxygen by the electron transport chain complexes. The transfer of electrons through the mitochondrial complexes I–IV located in the inner mitochondrial membrane provides the energy to generate an H$^+$ gradient across the inner mitochondrial membrane, which creates an inter-membrane mitochondrial potential ($\Delta$Ψ) functional to ATP production. Thus we measured $\Delta$Ψ by live staining HDMECs transfected with si-NRP1, si-VEGFR2, or si-control with the fluorescent dye tetramethylrhodamine methyl ester (TMRM), whose accumulation into the mitochondria depends on $\Delta$Ψ (Scaduto and Grotyohann, 1999). Accordingly, treatment of HDMECs with the electron transport chain uncoupler carbonyl cyanide m-chlorophenylhydrazone completely abrogated TMRM mitochondrial accumulation (Figure S2A). Confocal analysis showed that NRP1 downregulation, but not VEGFR2 knockdown, significantly reduced TMRM staining compared with si-control (Figures 2A and 2B). Together, these data demonstrate that NRP1 regulates mitochondrial membrane potential and suggest that NRP1 promotes mitochondrial function in a VEGF-independent manner.

As NRP1 downregulation reduced the area and volume of the mitochondrial network (Figures 1E and 1F), we investigated whether the decreased TMRM staining observed in ECs lacking NRP1 was due to a reduced mitochondrial content or to a genuine reduction in the proton motive force. Thus we co-labeled HDMECs and human umbilical vein endothelial cells (HUVECs) with TMRM and MitoTracker to measure simultaneously $\Delta$Ψ and mitochondrial content. Strikingly, NRP1 downregulation reduced the TMRM/MitoTracker ratio in HDMECs (Figures 2C and 2D) and HUVECs (Figures S2B and S2C). Furthermore, downregulation of NRP1 in HDMECs with two different NRP1-targeted siRNAs (Figure S2D) confirmed a reduction of TMRM/MitoTracker staining in cells lacking NRP1 expression (Figures S2E and S2F), indicating that the mitochondrial phenotype observed is not due to siRNA off-target effects. Together, these data indicate that lack of NRP1 expression in EC decreases mitochondrial proton motive force independently of the reduction in mitochondrial content.

As oxidative damage reduces mitochondrial activity and disrupts the organization of the mitochondrial network (Jendrach et al., 2008), we investigated whether NRP1 downregulation induces mitochondrial ROS production. HDMECs expressing or lacking NRP1 were live stained with the mitochondria-specific dye MitoSOX, which becomes fluorescent upon superoxide-mediated oxidation (Figure 2E). Strikingly, HDMECs lacking NRP1 expression showed significantly higher mitochondrial ROS compared with control, indicating that NRP1 expression suppresses mitochondrial ROS production (Figures 2E and 2F). Because inhibition of the endogenous antioxidant cellular system could lead to increased ROS levels, we investigated the role of NRP1 and VEGF signaling in the expression of the antioxidant enzymes superoxide dismutase 1 (SOD1), SOD2, and NRF2 in HDMECs. Interestingly, NRP1 downregulation, but not VEGFR2 knockdown, significantly reduced SOD1 expression compared with control cells (Figure 2G), whereas SOD2 and NRF2 expression was significantly reduced in cells transfected with either NRP1 or VEGFR2 siRNA (Figure 2G). Then, we investigated the expression of heme oxygenase 1 (HO-1), which is known to protect against oxidative stress and whose expression is strongly induced by a wide array of pro-oxidant and inflammatory stimuli (Luo et al., 2017). Downregulation of NRP1 induced a 10-fold upregulation of HO-1 expression compared with si-control, whereas VEGFR2 knockdown had no effect on HO-1 expression (Figure 2G). Accordingly, HO-1 protein level was significantly upregulated in HDMECs si-NRP1 (Figures S2G and S2H). Taken together, these data suggest that NRP1- and VEGF-mediated signaling pathways cooperate to maintain the cellular antioxidant defense system in HDMECs and that NRP1 loss induces an oxidative stress response that leads to HO-1 upregulation in ECs.

To further study the role of NRP1 in oxidative stress, we investigated whether NRP1 loss induces oxidative stress in vivo by measuring oxidative stress in the Tg(fli1a:EGFP)$^{y5}$-labeled vasculature of n$^{1a}$e1485/sa1485 mutant (n$^{1a}$e$^{-}$) zebrafish embryos. Live transgenic embryos at 3 days post-fertilization (dpf) were stained with CellROX dye, which detects generalized oxidative stress (Mugoni et al., 2014). To measure ROS specifically in the vasculature, we quantified CellROX fluorescence in isolated GFP-positive territories obtained...
Figure 2. NRP1 Regulates Mitochondrial Activity and Suppresses Oxidative Stress

(A) HDMECs transfected with si-NRP1, si-VEGFR2, or si-control were incubated with 100 nM TMRM and DRAQ5 (blue) and live imaged with a confocal microscope; scale bar, 20 μm.

(B) Integrated density of TMRM signal per cell was quantified and expressed as percentage (mean ± SEM; n = 4) of si-control.

(C) HDMECs transfected with siNRP1 or si-control were incubated with 100 nM TMRM and 300 nM MitoTracker Deep Red FM; scale bar, 20 μm.

(D) TMRM and MitoTracker Deep Red FM integrated density was calculated, and the TMRM/MitoTracker ratio visualized in the graph (mean ± SEM; n = 4).

(E) HDMECs transfected with si-NRP1 or si-control were incubated with 5 μM MitoSOX (red and gray) and counterstained with Hoescht 33342 (blue); scale bar, 20 μm.

(F) Integrated density of the MitoSOX signal per cell was quantified and expressed as percentage relative to si-control (mean ± SEM; n = 3).

(G) Quantification of superoxide dismutase-1 and 2 (SOD1, SOD2), NRF2, and heme oxygenase-1 (HO-1) mRNA by RT-qPCR in HDMECs si-NRP1 or si-control expressed as fold change of si-control (mean ± SEM; n = 3).

(H) Tg(fli1a:egfp)y5 wild-type and nrp1a^sa1485 zebrafish embryos at 3 dpf were incubated with 2.5 μM CellROX (gray) in 10% DMSO for 45 min before imaging; scale bars, 40 μm. (H') Higher-magnification images of area indicated in the square box in H; white arrows indicate ECs in ISV with high CellROX staining.

(I) CellROX mean intensity was quantified in optical z stacks in n = 16 embryos from three independent experiments after applying a mask to quantify CellROX-positive areas and volumes (mean ± SEM) within the vasculature.

(J) HDMECs treated with mitoTEMPO 10 μM for 24 hr after 48 hr from transfection with si-NRP1 or si-control were incubated with 100 nM TMRM (gray); scale bar, 20 μm.

(K) Integrated density of the TMRM signal per cell was quantified and normalized to cell number determined by manual counting using high-contrast images (panel J, green images) and expressed as percentage relative to si-control (mean ± SEM; n = 3).

*p < 0.05, ***p < 0.001; Student’s t test. See also Figure S2.)
by applying a virtual mask to the z stacks acquired by high-resolution confocal microscopy. Quantification of CellROX in the masked GFP-positive 3D projections showed that Tg(fli1a:EGFP)ECKO nrp1a−/− embryos had significantly higher CellROX signal within the vasculature compared with control embryos (Figures 2H and 2I). Furthermore, ECs in the intersomitic vessels (ISV) of nrp1a−/− knockout embryos were highly positive for CellROX (white arrows, Figure 2H), suggesting that the migratory ECs forming the ISVs are likely more susceptible to oxidative stress upon NRP1 deletion. These data demonstrate that NRP1 reduces oxidative stress in vivo and prompted us to investigate the molecular mechanism by which NRP1 regulates the redox status in ECs.

Because NRP1 downregulation reduces mitochondrial activity (Figures 2A–2D) and induces oxidative stress (Figures 2F–2I), we hypothesized that the increased oxidative stress observed in NRP1-deficient ECs damages the mitochondria and results in reduced mitochondrial activity. Thus, we measured ΔΨ in HDMECs expressing or lacking NRP1 and treated with the mitochondria-targeted antioxidant mitoTEMPO (Figure 2J), which is known to preserve mitochondrial membrane potential in oxidative stress conditions (Dikalova et al., 2010). Strikingly, mitoTEMPO treatment of HDMECs si-NRP1 significantly increased ΔΨ to a level similar to control (Figures 2J and 2K), indicating a recovered mitochondrial membrane potential in NRP1-deficient HDMECs following the mitoTEMPO treatment. These data suggest that ROS induce mitochondrial damage, which results in lowered mitochondrial activity in NRP1-deficient HDMECs.

To further investigate the role of NRP1 in the mitochondria of ECs, we used a mass-spectrometry-based post-translation modification analysis (PTMscan) approach to analyze changes in serine phosphorylation in the proteome of HDMECs transfected with si-NRP1 or si-control. We found that NRP1 downregulation affected serine phosphorylation of several mitochondrial enzymes (Figure S2, Table S1). Phosphorylation of ATPase family AAA-domain-containing protein 1 and of the precursor of NADH dehydrogenase flavoprotein 3 isoform b was affected. Furthermore, NRP1 knockdown reduced pyruvate dehydrogenase E1 component subunit alpha isoform 2 phosphorylation, which is known to inhibit pyruvate dehydrogenase enzymatic activity (Akhmedov et al., 2012). Strikingly, the mitochondrial-specific ATP-binding cassette (ABC) subfamily B member 8 (ABCB8) was 48 times less phosphorylated in HDMECs lacking NRP1 compared with si-control (Figures 2J and 2K), indicating a recovered mitochondrial membrane potential in NRP1-deficient HDMECs following the mitoTEMPO treatment. These data suggest that ROS induce mitochondrial damage, which results in lowered mitochondrial activity in NRP1-deficient HDMECs.

NRP1 Interacts with the ATP-Binding Cassette Protein ABCB8

Given that NRP1 loss reduces phosphorylation of ABCB8, we hypothesized that NRP1 regulates iron levels and iron-induced oxidative stress via ABCB8 in ECs. We first confirmed that ABCB8 is expressed in HDMECs and localizes in the mitochondria by co-staining HDMECs for ABCB8 and TOM20 (Figure S2J). We then investigated ABCB8 serine phosphorylation in HDMECs si-NRP1 or si-control by PLA using an anti-phosphoserine and an anti-ABCB8 antibody or control IgG (Figure 3A). In accordance with PTMscan data, the PLA signal detected in HDMECs si-NRP1 was significantly reduced compared with HDMECs si-control (Figure 3B). Because the changes in ABCB8 phosphorylation levels detected by PTMscan and PLA in HDMECs lacking NRP1 could result from a reduction in ABCB8 expression, we investigated whether NRP1 downregulation reduces ABCB8 transcript and protein levels. NRP1 downregulation had no effect on ABCB8 mRNA level (Figure 3C), whereas ABCB8 protein levels were significantly reduced in HDMECs lacking NRP1 compared with control (Figures 3D and 3E), indicating that the reduced levels of ABCB8 phosphorylation could be caused by a decrease in ABCB8 expression. To examine if NRP1 promotes ABCB8 protein expression in vivo, we analyzed ABCB8 protein levels in aortas of adult conditional Nrp1-null mice lacking (Nrp1WT) or expressing a tamoxifen-inducible, endothelial-specific Cre transgene (Nrp1ECKO). NRP1 and ABCB8 staining was performed on whole-mount aortas where ECs were counterstained with PECAM (Figures 3F and S1H). Tamoxifen treatment significantly reduced NRP1 expression in ECs of Nrp1ECKO compared with Nrp1WT control littermates, indicating that NRP1 was efficiently depleted. Strikingly, ABCB8 expression was significantly reduced in the endothelium of Nrp1ECKO compared with Nrp1WT littermates (Figures 3F and 3G). Taken together, these data demonstrate that NRP1 regulates ABCB8 protein levels in vitro and in vivo.
Because ABCB8 is a mitochondria-specific protein and a subcellular pool of NRP1 localizes in the mitochondria, we investigated whether NRP1 forms a protein complex with ABCB8 in HDMECs. Immunoprecipitation analysis performed by pulling down endogenous NRP1 and by probing the immunoprecipitated fraction for NRP1 and ABCB8 showed that NRP1 and ABCB8 form a protein complex (Figure 3H). PLA

Figure 3. NRP1 Localizes into the Mitochondria and Interacts with ABCB8

(A) PLA for ABCB8 and phosphoserine in HDMECs si-control or si-NRP1; PLA with IgG isotypes was performed as control; scale bar, 20 μm.
(B) PLA signal (gray) per cells (mean ± SEM) was measured in a minimum of 177 cells from two independent experiments; # = number of cells analyzed.
(C) Quantification of ABCB8 mRNA by RT-qPCR in HDMECs si-NRP1 or si-control; n = 3.
(D) HDMEC si-NRP1 and si-control were stained for ABCB8 (green) and counterstained with DAPI (blue); scale bars, 20 μm.
(E) Integrated density of ABCB8 signal was quantified and expressed as percentage relative to si-control (mean ± SEM; n = 3).
(F) Aortas of Nrp1fl/fl (Nrp1WT) or Nrp1fl/fl;Cdh5(PAC)-iCreERT2 (Nrp1ECKO) littermates injected daily with tamoxifen for 5 days and sacrificed after 1 month from injections were immunostained for NRP1, ABCB8, and PECAM; scale bar, 30 μm.
(G) NRP1 and ABCB8 pixel number and intensity were measured in optical z stacks, normalized to DAPI, and expressed as percentage of Nrp1WT (mean ± SEM; n ≥ 3 mice each genotype; **p < 0.005, ***p < 0.001, two-way ANOVA).
(H) Co-immunoprecipitation of endogenous NRP1 and ABCB8 protein from lysates of HDMECs performed with an anti-NRP1 antibody, followed by immunoblotting for NRP1 and ABCB8 (n = 3).
(I) PLA for NRP1 and ABCB8 in HDMECs si-control or si-NRP1. PLA with IgG isotypes was performed as control; scale bar, 20μm.
(J) Average PLA signal (gray) per cells (mean ± SEM) was measured in a minimum of 59 cells from four independent experiments. # = number of cells analyzed; *p < 0.05, **p < 0.005, ***p < 0.001, n.s., not significant; Student’s t test. See also Figures S1 and S2.
confirmed the protein-protein interaction observed by co-immunoprecipitation analysis (Figures 3I and 3J). These data further demonstrate that NRP1 localizes in the mitochondria and show that NRP1 interacts with ABCB8; the results also strongly suggest that the formation of this complex promotes ABCB8 function. Furthermore, the data suggest that NRP1 suppresses mitochondrial iron accumulation via ABCB8, thus preventing iron-dependent oxidative stress.

NRP1 Regulates Iron Homeostasis and Suppresses Iron-Dependent Oxidative Stress in ECs

To investigate whether NRP1 regulates iron homeostasis, we measured intracellular ferrous (Fe^{2+}) and ferric (Fe^{3+}) content in HDMECs lacking or expressing NRP1 using a ferene S-based colorimetric assay (Bai et al., 2017; Ichikawa et al., 2012). Intracellular iron was significantly higher in HDMECs downregulated for NRP1 expression compared with control (Figure 4A), indicating that NRP1 loss results in iron accumulation. To further investigate whether NRP1 downregulation induces mitochondrial iron accumulation we measured Fe^{2+} in HDMECs expressing or lacking NRP1 expression by incubating ECs with Mito-FerroGreen, a mitochondria-specific iron probe that becomes fluorescent when reacting with labile mitochondrial Fe^{2+} (Hirayama et al., 2018). Co-staining of HDMECs with Mito-FerroGreen and MitoTracker confirmed a complete mitochondrial localization of Mito-FerroGreen in HDMECs (Figure 4B). In agreement with the increased intracellular iron observed in HDMECs si-NRP1 (Figure 4A), NRP1 downregulation induced a significant increase in mito-FerroGreen staining, indicating that loss of NRP1 expression induces mitochondrial iron accumulation in ECs (Figures 4B and 4C).

Then we investigated the expression of iron transporters known to modulate intracellular iron levels. No change was observed in the mRNA levels and protein expression of transferrin receptor 1, which mediates cellular iron uptake (Figures S3A and S3B). Expression of ferroportin-1, which regulates EC iron efflux, was significantly increased at the protein level (Figure 4D), but unchanged at the mRNA level (Figure S3A), following NRP1 downregulation. Interestingly, NRP1 downregulation significantly increased the expression of mitochondria-specific iron importer Mitoferrin-1 but had no effect on Mitoferrin-2 expression (Figure S3C). Taken together these data suggest that loss of NRP1 induces iron accumulation by dysregulating iron influx-efflux balance in ECs.

To investigate whether iron accumulation reduces mitochondria activity in HDMECs downregulated for NRP1 expression, we measured the mitochondrial membrane potential \( \Delta \Psi \) in HDMECs expressing or lacking NRP1 and treated with the iron chelator deferoxamine (Figure 4F). As previously shown (Figures 2A–2D), NRP1 downregulation significantly decreased the \( \Delta \Psi \)-dependent TMRM staining (Figures 4F and 4G). Strikingly, deferoxamine treatment of HDMECs si-NRP1 rescued the TMRM staining to a level comparable to HDMECs si-control (Figures 4F and 4G), indicating that iron-mediated ROS production causes mitochondrial damage, which results in reduced \( \Delta \Psi \). Similarly, deferoxamine treatment rescued \( \Delta \Psi \) in HUVECs lacking NRP1 (Figures S3D and S3E). Thus we investigated whether iron induces ROS production by measuring mitochondrial ROS in HDMECs si-NRP1 treated with the iron chelator deferoxamine. As previously shown (Figures 2E and 2F), MitoSOX live-stained HDMECs lacking NRP1 expression have significantly higher mitochondrial superoxide level compared with control cells (Figures 4H and 4I). Importantly, deferoxamine treatment normalized superoxide levels in HDMECs si-NRP1 to levels similar to control cells (Figures 4H and 4I). Taken together these data demonstrate that lack of NRP1 induces iron-dependent oxidative stress, which causes a decrease of the mitochondrial activity and increases mitochondrial ROS levels.

NRP1 Regulates Iron Homeostasis via ABCB8

To further investigate whether NRP1 regulates iron-dependent oxidative stress via ABCB8, we downregulated ABCB8 expression using siRNA in HDMECs (si-ABCB8). ABCB8 mRNA, immunostaining, and immunoblotting analyses showed that HDMECs transfected with si-ABCB8 had significantly reduced ABCB8 expression (Figures 5A–5C and S3F). Then we investigated whether ABCB8 downregulation decreases mitochondrial \( \Delta \Psi \) similarly to NRP1 knockdown and whether deferoxamine treatment could normalize \( \Delta \Psi \) in HDMECs and HUVECs knockdown for ABCB8. HDMECs and HUVECs lacking ABCB8 expression showed reduced TMRM staining compared with control (Figures 5D, 5E, S3G, and S3H) similarly to NRP1 downregulation (Figures 2B–2D, 4F, and 4G). Strikingly, deferoxamine treatment restored \( \Delta \Psi \) of HDMECs and HUVECs si-ABCB8 to levels comparable with those of control cells (Figures 5D, 5E, S3G, and S3H). These data indicate that lack of ABCB8 or NRP1 similarly induces an iron-mediated decrease in mitochondrial \( \Delta \Psi \) and strongly suggest that NRP1 and ABCB8 act on the same signaling pathway.
Figure 4. NRP1 Regulates Iron Homeostasis And Iron-Dependent Oxidative Stress

(A) Intracellular total iron (Fe²⁺ plus Fe³⁺) of HDMECs si-control or si-NRP1 expressed as percentage relative to si-control (mean ± SEM; n = 3).

(B) HDMECs si-NRP1 or si-control were incubated with 5 μM Mito-FerroGreen (gray) and 300 nM MitoTracker Deep Red FM (red); scale bar, 20 μm.

(C) Mito-FerroGreen fluorescent signal per cell was quantified and expressed as percentage relative to si-control (mean ± SEM; n = 3).

(D) HDMECs si-NRP1 or si-control were stained for ferroportin-1 (green or gray) and counterstained with DAPI (blue); scale bar: 20 μm.

(E) Integrated density of ferroportin-1 was normalized to DAPI and expressed as fold change of si-control (mean ± SEM; n = 4).

(F) HDMECs treated with deferoxamine 100 μM for 24 hr after 48 hr from transfection with si-NRP1 or si-control were incubated with 100 nM TMRM (gray); scale bars, 20 μm.

(G) Integrated density of the TMRM signal normalized to cell number determined by manual counting using high-contrast images (panel F, green images) and expressed as percentage relative to untreated si-control (mean ± SEM; n = 4).

(H) HDMECs si-control or si-NRP1 untreated or treated with deferoxamine 100 μM for 24 hr were incubated with 5 μM MitoSOX (red), counterstained with Hoescht 33342 (blue); scale bar: 20 μm.

(I) Integrated density of the MitoSOX signal expressed as percentage relative to untreated si-control (mean ± SEM; n = 4).

*p < 0.05, **p < 0.001; Student’s t test. See also Figure S3.
Figure 5. NRP1 Regulates Iron-Dependent Oxidative Stress via ABCB8

(A) Quantification of ABCB8 mRNA by RT-qPCR in HDMECs si-ABCB8, si-NRP1, or si-control. Transcripts levels were expressed as fold change of si-control (mean ± SEM; n = 3).

(B) Immunostaining for ABCB8 (green) in HDMECs si-ABCB8 or si-control counterstained with DAPI (blue); scale bar, 20 μm.

(C) ABCB8 integrated density in optical z stacks was normalized to DAPI integrated density and expressed as percentage relative to si-control (mean ± SEM; n = 3).

(D) HDMECs treated with deferoxamine 100 μM for 24 hr, 48 hr after transfection with si-ABCB8 or si-control were incubated with 100 nM TMRM (gray); scale bar, 20 μm.

(E) Integrated density of the TMRM signal was normalized to cell number determined by manual counting using high-contrast images (Figure 5D, green panels) and expressed as percentage (mean ± SEM; n = 4).

(F) HDMECs si-ABCB8 or si-control were incubated with 5 μM MitoSOX (red) and counterstained with Hoescht 33342 (blue); n = 4; scale bar, 20 μm.

(G) Integrated density of the MitoSOX signal was quantified as percentage of si-control (mean ± SEM; n = 4).

(H) Quantification of NRP1 and ABCB8 mRNA by RT-qPCR in HDMECs single or double transfected with si-NRP1 and si-ABCB8 or si-control (mean ± SEM; n = 3).

(I) HDMECs single or double transfected with si-ABCB8 and si-NRP1 or si-control were incubated with 100 nM TMRM (gray); scale bar, 20 μm.

(J) Integrated density of the TMRM signal was normalized to cell number determined by manual counting using high-contrast images (panel I, green images) and expressed as percentage (mean ± SEM; n = 3).

*p < 0.05, ***p < 0.001; n.s., not significant; Student’s t test. See also Figure S3.
Because ABCB8 downregulation induces iron-mediated ROS production in cardiomyocytes and melanoma cells (Ichikawa et al., 2012, 2014), we investigated whether ABCB8 regulates iron-dependent oxidative stress by measuring mitochondrial superoxide level in HDMECs expressing or lacking ABCB8 and treated with deferoxamine. MitoSOX live-staining analysis showed that ABCB8-deficient HDMECs had significantly higher MitoSOX staining compared with si-control (Figures 5F and 5G), similarly to NRP1 downregulation (Figures 2E and 2F), suggesting that both NRP1 and ABCB8 regulate iron-mediated ROS production in ECs. Accordingly, deferoxamine completely inhibited superoxide production in HDMECs si-ABCB8 (Figures 5F and 5G). These data demonstrate that ABCB8 downregulation induces iron-dependent ROS production in ECs and suggest that NRP1 regulates these processes through ABCB8.

To further investigate this hypothesis, we measured mitochondrial ΔΨ and ROS in HDMECs with a simultaneous knockdown for ABCB8 and NRP1. Downregulation of both NRP1 and ABCB8 (Figure 5H) had no additive effect in inhibiting mitochondrial ΔΨ compared with HDMECs lacking NRP1 or ABCB8 only (Figures 5I and 5J), suggesting that NRP1 and ABCB8 act on the same cellular pathway.

**NRP1 and ABCB8 Loss Induces Iron-Dependent Premature Senescence in ECs**

Cellular senescence can be prematurely induced by telomere-independent mechanisms, which include excessive oxidative stress and mitochondrial dysfunction (Erusalimsky, 2009). Thus we hypothesized that loss of NRP1 could result in premature senescence in ECs, and we investigated whether NRP1-deficient ECs presented the hallmarks of senescence. Cellular senescence is characterized by elevated senescence-associated β-galactosidase (SA-β-gal) activity (Dimri et al., 1995; Ota et al., 2008; Warboys et al., 2014), increased p16 levels (Chen et al., 2006; Song et al., 2008), reduction of SIRT1 expression (Ota et al., 2008), and reduced proliferation. NRP1-deficient HDMECs showed an increased number of SA-β-gal-positive cells compared with control (Figures 6A and 6B) alongside increased p16 levels and reduced SIRT1 expression (Figures 6C–6E). Furthermore, cell counting analysis showed a reduced cell growth rate of NRP1-downregulated HDMECs compared with control under normal growth conditions (Figure 6F). Because it has been previously reported that NRP1 is required to mediate anti-apoptotic signals in serum-starved ECs (Wang et al., 2007), we measured the apoptosis marker annexin-V (Koopman et al., 1994) by fluorescence-activated cell sorting (FACS) to determine whether the reduced cell growth observed in NRP1-deficient ECs was due to increased apoptosis also in normal growth conditions. The number of cells undergoing apoptosis was similar in HDMECs si-NRP1 and si-control (Figure 6G), suggesting that the reduced cell growth observed in normal growth conditions is not caused by increased apoptosis. Importantly, FACS analysis of bromodeoxyuridine-labeled HDMECs si-NRP1 or si-control showed that NRP1 deficiency significantly reduced the number of proliferating cells in HDMECs si-NRP1 compared with controls (Figure 6H). Thus NRP1 loss reduces EC proliferation without inducing apoptosis in normal growth conditions.

Because EC proliferation was affected by NRP1 loss, we investigated whether the expression of cyclins was affected by NRP1 knockdown. In agreement with the reduced cell growth, immunoblotting analysis showed reduced cyclin D1 and cyclin B1 levels and a concomitant increase in cyclin D2 expression in HDMECs si-NRP1 compared with si-control (Figures 6I and 6J). Thus loss of NRP1 affects cyclin expression and therefore cell cycle progression in ECs.

To further investigate the role of NRP1 in EC senescence, we measured p16 protein level and the number of SA-β-gal-positive cells also in primary mouse lung endothelial cells (MLECs) isolated from mice genetically deficient for NRP1 in ECs (Nrp1^{ECKO}) and from control littermates (Nrp1^{WT}). Nrp1^{ECKO} MLECs showed significantly higher p16 protein expression (Figures 6K and 6L) and increased number of SA-β-gal-positive cells (Figures 6M and 6N) compared with MLECs isolated from Nrp1^{WT} littermates. Taken together these data demonstrate that loss of NRP1 induces premature senescence.

We then investigated whether by regulating iron homeostasis the NRP1-ABCB8 pathway protects ECs from premature senescence. SA-β-gal staining showed that NRP1 or ABCB8 downregulation similarly increased the number of SA-β-gal-positive HDMECs (Figures 6O and 6P). Furthermore, treatment of HDMECs lacking both NRP1 and ABCB8 with deferoxamine reduced SA-β-gal-positive cells to a level similar to untreated si-control (Figures 6O and 6P). These data show that NRP1-ABCB8 pathway suppresses iron-induced ECs senescence.
Figure 6. NRP1 Suppresses Iron-Dependent Premature Senescence via ABCB8

(A) SA-β-gal staining in HDMECs si-control or si-NRP1 72 and 120 hr after transfection.
(B) Quantification of SA-β-gal-positive cells (mean ± SEM; n = 3).
(C) Representative immunoblots for NRP1, p16, and SIRT1 of HDMECs si-control or si-NRP1.
(D) Quantification of p16 expression level as pixel intensity relative to GAPDH pixel intensity (mean ± SEM; n = 4).
(E) Immunofluorescence for NRP1 (green) and p16 (red) together with DAPI staining; scale bar, 20 µm; n = 2.
(F) Cell counting assay at 72 and 120 hr after transfection in HDMECs si-control or si-NRP1 (mean ± SEM; n = 3).
(G) FACS analysis of annexin-V-positive cells in HDMECs si-control or si-NRP1 (mean ± SEM; n = 3).
(H) Analysis of bromodeoxyuridine (BrdU)-positive cells in HDMECs si-NRP1 or si-control (mean ± SEM; n = 4).
(I) Representative immunoblotting for cyclin D1, cyclin B1, and CHD5 with GAPDH serving as a loading control of HDMECs si-control or si-NRP1.
(J) Quantification of the indicated protein expression levels as pixel intensity relative to GAPDH pixel intensity (mean ± SEM; n = 4).
(K) Representative immunoblotting for the indicated proteins of MLECs from Nrp1^{ECKO} and Nrp1^{WT} littermates.
(L) Quantification of p16 total levels as pixel intensity relative to GAPDH (mean ± SEM; n = 4).
(M) SA-β-gal assay of MLECs from Nrp1^{ECKO} and Nrp1^{WT} littermates.
(N) Quantification of SA-β-gal-stained MLECs after four and eight tissue culture passages.
(O) SA-β-gal staining in HDMECs double transfected for 24 hr with si-NRP1, si-ABCB8, or si-control and treated with deferoxamine 100 µM for 48 hr.
(P) Quantification of SA-β-gal-positive cells (mean ± SEM; n = 3).

*p < 0.05, **p < 0.01, n.s., not significant; Student’s t test.
DISCUSSION

Despite oxygen availability, ECs mainly rely on anaerobic glycolysis to meet their energy demand and to produce ATP (De Bock et al., 2013). Thus although mitochondria provide a limited contribution to energy production in ECs, they are essential for EC function, because altering mitochondrial dynamics contributes to endothelial dysfunction (Shenouda et al., 2011). Accordingly, ECs lacking MFN1 show reduced VEGF-induced angiogenesis and inhibited AKT-dependent activation of endothelial nitric oxide synthase (Lugus et al., 2011). Here we show that NRP1 regulates mitochondrial activity and dynamics. ECs lacking NRP1 fail to form the complex mitochondrial network observed in control ECs and show a reduced level of MFN1. Mitochondrial dysfunction plays a role in the onset of cellular senescence, and preventing mitochondrial dysfunction delays replicative senescence in human primary cells (Passos et al., 2007). Furthermore, excessive production of ROS is associated with mitochondrial dysfunction and with the induction of p16INK4A-dependent senescence (Davalli et al., 2016).

Cellular senescence limits the capacity of tissues to undergo repair by cell proliferation and thereby accelerates age-related degenerative diseases such as sarcopenia (Kudryashova et al., 2012), osteoarthritis (Price et al., 2002), pulmonary fibrosis (Tsuji et al., 2010), and Alzheimer disease (Bhat et al., 2012). In the aging vasculature, senescent ECs accumulate in atherosclerotic lesions and likely contribute to disease progression by creating a pro-inflammatory and pro-thrombotic environment (Minamino et al., 2002; Vasile et al., 2001; Warboys et al., 2014). Here we show that ECs lacking NRP1 show the hallmarks of cellular senescence, including high levels of p16 and decreased SIRT1 expression alongside deregulated cyclin expression, reduced proliferation, as well as an increased SA-b-gal staining.

Furthermore, we show that NRP1 prevents mitochondrial superoxide production and EC senescence by promoting iron homeostasis via the mitochondrial transporter ABCB8 (Figure 7). As a pool of NRP1 localizes in the mitochondria and interacts with the mitochondrial inner membrane transporter ABCB8, the NRP1-ABCB8 complex likely forms in the inner mitochondrial membrane compartment. NRP1 downregulation reduces ABCB8 protein expression and phosphorylation. The ABCB8 reduction observed in NRP1-deficient ECs could be explained on one hand by the reduced mitochondria content, and on the other hand by the disruption of the ABCB8/NRP1 complex, which could promote localization of ABCB8 in the mitochondria or prevent ABCB8 protein degradation. Importantly, because HDMECs si-NRP1 show a partial reduction in ABCB8 protein content but PTMscan and PLA analyses display an almost complete inhibition in ABCB8 phosphorylation, our data suggest that the decreased phosphorylation of ABCB8 observed in HDMECs si-NRP1 could be caused by a combination of the reduced ABCB8 protein level with an additional mechanism that could inhibit ABCB8 phosphorylation in NRP1-deficient ECs.
Treatment with the iron chelator compound deferoxamine restores the mitochondrial membrane potential of NRP1-deficient HDMECs and HUVECs and abrogates mitochondrial superoxide production. Deferoxamine has been shown to promote blood flow recovery in a hindlimb ischemia mouse model (Ikeda et al., 2011) and to increase hypoxia-inducible transcription factor 1, VEGFA, and COX-2 levels in ischemic skeletal muscle and in macrophages (Asikainen et al., 2005; Woo et al., 2006). A role for iron has also been proposed in the pathogenesis of atherosclerosis (Kiechl et al., 1997; Lee et al., 1999), and deferoxamine treatment improved nitric oxide-mediated, endothelium-dependent vasodilation in patients with coronary artery disease (Duffy et al., 2001).

By showing that deferoxamine restores mitochondrial membrane potential and reduces ECs senescence in NRP1-deficient ECs (Figure 7), our data raise the possibility that targeting iron metabolism could be a promising strategy to prevent ECs senescence and preserve endothelial function.

The function of NRP1 in regulating mitochondrial homeostasis and iron metabolism independently of VEGFR2 signaling expands the current model, which suggests that NRP1 promotes several signals in ECs and is not acting exclusively as a VEGF co-receptor (Aspalter et al., 2015; Hu et al., 2007; Raimondi et al., 2014, 2015, 2016). Because the NRP1-ABCB8 pathway is essential to prevent iron-induced mitochondrial dysfunction, our data suggest that in addition to its well-characterized role in angiogenesis, arteriogenesis (Fantin et al., 2014; Kawasaki et al., 1999; Lanahan et al., 2013; Raimondi, 2014), and vascular permeability (Fantin et al., 2017; Roth et al., 2016), NRP1 regulates a fundamental pathway that promotes ECs homeostasis.

In ECs, mitochondria function as a metabolic hub (Davidson, 2010; De Bock et al., 2013; Quintero et al., 2006). Mitochondria are involved in the production of aspartate and glutamate needed for deoxynucleotide synthesis (Rohlenova et al., 2017; Schoors et al., 2015), in the regulation of glutamine metabolism whose inhibition causes vessel-sprouting defects due to impaired proliferation and migration (Huang et al., 2017), and in iron metabolism. Because Fe/S clusters and heme’s precursor biosynthesis occurs in the mitochondria, physiological mitochondrial iron levels are maintained through the activity of mitochondria-specific iron importers and exporters. Mitoferrin-1 and mitoferrin-2 mediate iron uptake in fibroblasts, murine embryonic stem cells, and erythroleukemia cells (Chen et al., 2010; Paradkar et al., 2009), whereas recent evidence shows that the mitochondrial inner membrane transporter ABCB8 regulates ionic iron export and protects mitochondria from iron overload in melanoma cells and cardiomyocytes (Ardehali et al., 2005; Ichikawa et al., 2012, 2014). Accordingly, mouse mutants lacking ABCB8 expression in cardiomyocytes develop cardiomyopathy due to increased mitochondrial iron, which results in iron-dependent ROS production and mitochondrial dysfunction (Ichikawa et al., 2012). Our data show that ABCB8 plays a key role in iron homeostasis also in ECs. Furthermore, our data suggest a profound role of NRP1 in regulating mitochondrial iron because its downregulation simultaneously increases the mitochondrial importer mitoferrin-1 transcript and decreases ABCB8 protein level. As the data presented here and in previous reports (Ichikawa et al., 2012, 2014) show that ABCB8 prevents iron-mediated mitochondrial damage, it is possible that by decreasing ABCB8-dependent iron export, NRP1 loss impairs mitochondrial function and therefore iron metabolism, thus triggering a compensatory response to increase transcription of the mitochondrial iron importer mitoferrin-1 to restore iron metabolism and of ferroportin-1 to maintain physiological intracellular iron levels.

Our data suggest that promoting NRP1-dependent signaling could be particularly relevant in age-related diseases characterized by increased oxidative stress or by deregulation of iron metabolism such as atherosclerosis, vascular dementia, and Alzheimer disease. Oxidative stress and iron-mediated free radical production mediate neuronal death and gliosis. Furthermore, oxidative stress induces endothelial dysfunction in a model of cerebral ischemia (Jin et al., 2008). Importantly, patients with Alzheimer or Parkinson diseases have higher iron content, which correlates with increased ROS levels in areas of the brain prone to neurodegeneration (Manoharan et al., 2016). Recent evidence suggests that the neurodegenerative process observed in neurodegenerative diseases is initiated by blood-brain barrier dysfunction, caused by aging and cardiovascular conditions, resulting in increased oxidative stress, dysregulation of nitric oxide, inflammation, and altered paracellular permeability (Oakley and Tharakan, 2014; Sweeney et al., 2018). Whether NRP1 expression or activity is modulated in these diseases is unknown, and our work suggests that pathological downregulation of NRP1 could have detrimental consequences on EC homeostasis.
In conclusion, our data demonstrate an unexpected function of NRP1, which acts as a key regulator of mitochondria and iron homeostasis in ECs by suppressing iron accumulation and iron-dependent oxidative stress via ABCB8, independently of VEGF signaling. Our work suggests that the NRP1-ABCB8 pathway could protect ECs function from iron-dependent ROS-induced endothelial dysfunction and have a protective role in age-related diseases.

Limitation of the Study
To identify the NRP1-ABCB8 pathway and to investigate its role in ECs, we used an in vitro approach that relied on siRNA-mediated transient downregulation of NRP1 and ABCB8. This approach allows neither the long-term effects of NRP1 or ABCB8 downregulation in ECs nor the role of the NRP1/ABCB8 pathway in endothelial function in vivo to be studied. Although we have established that genetic manipulation of NRP1 expression prevents oxidative stress in a zebrafish model and protects ECs from senescence in an ex vivo model, whether the NRP1-ABCB8 pathway plays a role in physiological or pathological angiogenesis, or in homeostatic EC functions such as nitric oxide synthase activation, vascular permeability, and leukocyte-EC adhesion remains to be addressed. Furthermore, the mechanisms that modulate NRP1 expression in pathological contexts, such as neurodegenerative disorders or ischemia, are currently unclear and would need to be further investigated.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, three figures, and one table and can be found with this article online at https://doi.org/10.1016/j.isci.2018.12.005.

ACKNOWLEDGMENTS
The project was initiated when Dr. Raimondi was a BHF immediate fellow at UCL in Christiana Ruhrberg’s laboratory. We are grateful to the staff of the Biological Resources Units at the UCL and of Imperial College London for help with mouse husbandry. We thank the Facility for Imaging by Light Microscopy (FILM) at Imperial College London that is partly supported by funding from the Wellcome Trust (grant 104931/Z/14/Z) and BBSRC (grant BB/L015129/1). We thank Christiana Ruhrberg, Kirsty Naylor, Anastasia Lampropoulou, Alessandro Fantin, and Patric Turowski for the useful discussion during the development of the project. We also thank Elisabeth Genot for critical reading of the manuscript. This work was supported by a Medical Research Council grant (MR/L003775/1) to G.G. and S. W. Wilson and research fellowships from the British Heart Foundation (FS/13/35/30148, FS/16/22/32045) to C.R. The PTMscan analysis was supported by a PTMScan® Discovery grant awarded by Cell Signaling Technology to C.R.

AUTHOR CONTRIBUTIONS
T.I. and E.B. equally contributed as co-first authors and generated most of the data included in this manuscript. T.I. and E.B. performed and analyzed most of the immunoblots, qPCR, immunostainings, TMRM, and MitoTracker live-staining experiments and contributed to writing the manuscript. E.B. performed and analyzed immunostaining on mouse tissues. N.D.W. performed and analyzed TMRM and MitoTracker live-staining experiments. G.G. performed and analyzed zebrafish experiments. N.D.W. performed and analyzed proximity ligation assay experiments. V.S. isolated and cultured MLECs. A.C. investigated cyclin expression and helped with EC senescence assays. A.M.R. designed research and analyzed data. C.R acquired funding, supervised the project, designed and performed research, analyzed the data, and wrote the manuscript. All authors have read and commented on the manuscript.

DECLARATION OF INTERESTS
Authors declare no conflict of interest in relation to the work described in this manuscript.

Received: June 4, 2018
Revised: October 24, 2018
Accepted: December 4, 2018
Published: January 25, 2019
acts as a vascular permeability factor. Blood suppresses VEGF-mediated angiogenesis yet
J.R., and Cheresh, D.A. (2008). Semaphorin 3A
The following references appear in the Supplemental Information: Lawton and Weinstein, 2002; Stokes
SUPPORTING CITATIONS
J.A., and Verin, A.D. (2005). Neuropilin-1
Mirzapoiazova, T., Sham, J.S., Lee, C.G., Elias,
Becker, P.M., Waltenberger, J., Yachechko, R.,
Asikainen, T.M., Ahmad, A., Schneider, B.K., Ho,
Christofalo, V.J., Lorenzini, A., Allen, R.G., Torres,
Avram, A., Eskander, J., Bloomgarden, N.A.,
Hamza, I., and Dailey, H.A. (2012). One ring to rule
Beck, P.M., Waltenberger, J., Yachechko, R.,
Mirzapoiazova, T., Shan, J.S., Lee, C.G., Elias,
J.A., and Verin, A.D. (2005). Neurophin-1 regulates vascular endothelial growth factor-
mediated endothelial permeability. Circ. Res. 96,
1257–1265.
Begicic, R.R., and Falasca, M. (2017). ABC transporters in cancer stem cells: beyond chemoresistance. Int. J. Mol. Sci. 18, 2362.
References
Acevedo, L.M., Barillas, S., Weis, S.M., Gothert, J.R., and Cheresh, D.A. (2008). Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 117, 2674–2680.
Akhmedov, D., De Marchi, U., Wollheim, C.B., and Wiederkem, A. (2012). Pyruvate dehydrogenase epsilon alpha phosphorylation is induced by glucose but does not control metabolism-secretion coupling in INS-1E clonal beta-cells. Biochim. Biophys. Acta 1823, 1815–1824.
Al-Mehdi, A.B., Pastukh, V.M., Swiger, B.M., Reed, D.J., Patel, M.R., Bardwell, G.C., Pastukh, V.V., Alexeyev, M.F., and Gillespie, M.N. (2012). Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription. Sci. Signal. 5, ra47.
Ardehali, H., Xue, T., Dong, P., and Machamer, C. (2005). Targeting of the mitochondrial membrane proteins to the cell surface for functional studies. Biochem. Biophys. Res. Commun. 338, 1143–1148.
Asikainen, T.M., Ahmad, A., Schneider, B.K., Ho, W.B., Arend, M., Brenner, M., Gunzler, V., and White, C.W. (2005). Stimulation of Hif-1alpha, Hif-2alpha, and VEGF by prolyl 4-hydroxylase dysfunction-secretion coupling in INS-1E clonal beta-cells. Biochim. Biophys. Acta 1740, 9363–9367.
Avram, A., Eskander, J., Bloomgarden, N.A., Nazarewicz, R.R., McCann, L., Lewis, W., Harrison, J.T., Prahst, C., Lange, C.A., Liyanage, S.E., and Alevriadou, B.R. (2012). Mitochondrial fission in endothelial tip cells. Cell Metab. 15, 1577–1590.
Balogh, I., Tang, J., Dominici, F., Wu, Y., Neural crest-derived cells. Circ. Res. 67, 981–988.
Bektash, M., Ahluwalla, F.A., Al-Sheikh, A., and Auger, D.J. (2013). Functional recovery of the cardiovascular system after traumatic head injury. J. Neurotrauma 30, 433–444.
Bennett, J., Murphy, J., and McNew, J.A. (2009). Mitochondrial membrane proteins: membrane stability and metabolism. Annu. Rev. Physiol. 71, 85–115.
Berger, M., and Lasch, G. (2003). Mitochondrial protein import in eukaryotes: a complex interplay of proteins and mechanisms. Biochim. Biophys. Acta 1646, 65–75.
Bekiranov, S., and Vasquez, J. (2004). A biomarker for identification of senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A 91, 9363–9367.
Duffy, S.J., Biegeisen, E.S., Holtbrook, M., Russell, J.D., Gokce, N., Keaney, J.F., Jr., and Vita, J.A. (2001). Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103, 2799–2804.
Erusalimsky, J.D. (2009). Vascular endothelial senescence: from mechanisms to pathophysiology. J. Appl. Physiol. (1985) 106, 326–332.
Fanti, A., Herzog, B., Mahmoud, M., Yamaji, M., Plein, A., Denti, L., Ruhberg, C., and Zachary, I. (2016). Neurophin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development 141, 556–562.
Fanti, A., Lamprou, Olou, A., and Raimondi, C. (2010). Mitochondrial fission and fusion in mammals. Annu. Rev. Cell Dev. Biol. 22, 79–99.
Fenell, J., Huang, X., Hu, F., Vaziri, A., and Vaziri, A. (2000). Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1. Cell Death Dis. 5, e1180.
Fau, C., and Harrison, D.G. (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87, 840–844.
Cham, D.C. (2006). Mitochondrial fusion and fission in mammals. Annu. Rev. Cell Dev. Biol. 22, 79–99.
Chen, J., Huang, X., Halicka, D., Brodsky, S., Avram, E., Eskander, J., Bloomgarden, Z., Darzynekzwitz, Z., and Goligorsky, M.S. (2006). Contribution of p16INK4a and p21CIP1 pathways to induction of premature senescence of human endothelial cells: permissive role of p53. Am. J. Physiol. Heart Circ. Physiol. 290, H1575–H1586.
Chen, W., Dailey, H.A., and Paw, B.H. (2010). Ferrochelatase forms an oligomeric complex with mitoferrin-1 and Abcb10 for erythroid heme biosynthesis. Blood 116, 628–630.
Cristofalo, V.J., Lorenzini, A., Allen, R.G., Torres, C., and Tresini, M. (2004). Replicative senescence: a critical review. Mech. Ageing Dev. 125, 827–848.
Davalli, P., Mitic, T., Caporal, A., Lauriola, A., and D’Arca, D. (2016). ROS, cell senescence, and novel molecular mechanisms in aging and age-related diseases. Oxid Med. Cell. Longev. 2016, 3565127.
Davidson, S.M. (2010). Endothelial mitochondria and heart disease. Cardiovasc. Res. 88, 58–66.
De Bock, K., Geogiadou, M., and Carmeliet, P. (2013). Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 18, 634–647.
Dean, M., and Allikmets, R. (2001). Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33, 475–479.
Dikalova, A.E., Bikineyeva, A.T., Budzyn, K., Nazarewicz, R.R., McCann, L., Lewis, W., Harrison, D.G., and Dikalova, S.I. (2010). Therapeutic targeting of mitochondrial superoxide in ischemia. Circ. Res. 107, 106–116.
Dinni, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linkmens, M., Rubelj, I., Pereira-Smith, O., et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A 92, 9363–9367.
Duffy, S.J., Biegeisen, E.S., Holtbrook, M., Russell, J.D., Gokce, N., Keaney, J.F., Jr., and Vita, J.A. (2001). Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103, 2799–2804.
progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26, 5577–5586.

Huang, H., Vandekeere, S., Kalucza, J., Bierhaus, L., Zecchin, A., Bruning, U., Visnagri, A., Yuldasheva, N., Goveia, J., Cruys, B., et al. (2017). Role of glutamine and interlinked asparagine metabolism in vessel formation. EMBO J. 36, 2334–2352.

Ichikawa, Y., Bayeva, M., Ghanefer, M., Potin, V., Sun, L., Mutharasan, R.K., Wu, R., Khechaduri, A., Jairaj Naik, T.J., and Ardehali, H. (2012). Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export. Proc. Natl. Acad. Sci. U S A 109, 4152–4157.

Ichikawa, Y., Ghanefer, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S.V., Mutharasan, R.K., Naik, T.J., and Ardehali, H. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Invest. 124, 617–630.

Ikeda, Y., TAJIMA, S., Yoshida, S., Yamano, N., Kihira, Y., Ishizawa, K., Aihara, K., Tomita, S., Tsuji, K., and Tamaki, T. (2011). Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis 215, 339–347.

Jendrach, M., Mai, S., Pohl, S., Voth, M., and Berreth-Hahn, J. (2008). Short- and long-term alterations of mitochondrial morphology, dynamics and mtDNA after transient oxidative stress. Mitochondrion 8, 293–304.

Jin, G., Arai, K., Murata, Y., Wang, S., Stins, M.F., Lo, E.H., and van Leyen, K. (2008). Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke 39, 2538–2543.

Kawasaki, T., Kitsukawa, T., Bekku, Y., Matsuoka, Y., Sanbo, M., Yagi, T., and Fujisawa, H. (1999). A requirement for neuropilin-1 in embryonic vessel formation. Development 126, 4895–4902.

Kell, D.B. (2009). Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 2, 2.

Kiehl, S., Willeit, J., Egger, G., Poewe, W., and Oberhollenzer, F. (1997). Body iron stores and the risk of carotid atherosclerotic prospectively results from the Bruneck study. Circulation 96, 3300–3307.

Kitsukawa, T., Shimizu, M., Sanbo, M., Hirata, T., Taniguchi, M., Bekku, Y., Yagi, T., and Fujisawa, H. (1999). Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in neurovascular development and eye disease. J. Mol. Cell Cardiol. 31, 885–893.

Lee, T.S., Shiao, M.S., Pan, C.C., and Chau, L.Y. (1999). Iron-deficient diet reduces atherosclerotic lesions in apo-deficient mice. Circulation 99, 1222–1229.

Lill, R., Diekert, K., Kaut, A., Lange, H., Pelzer, W., Prohl, K., and Kispal, G. (1999). The essential role of mitochondria in the biogenesis of cellular iron-sulfur proteins. Biol. Chem. 380, 1157–1166.

Liu, Y., Li, H., Bubolz, A.H., Zhang, D.X., and Guttermann, D.D. (2008). Endothelial cytoskeletal elements are critical for flow-mediated dilation in human coronary arteries. Med. Biol. Eng. Comput. 46, 469–478.

Lugus, J.J., Ngho, G.A., Bachschmid, M.M., and Walsh, K. (2011). Mitofusins are required for angiogenic function and modulate different signaling pathways in cultured endothelial cells. J. Mol. Cell Cardiol. 51, 885–893.

Luo, Y., Lu, S., Dong, X., Xu, L., Sun, G., and Sun, X. (2017). Dihydrorhodamine protects human umbilical vein endothelial cells from injury through ERK and Akt mediated Nrf2/HO-1 signaling pathway. Apoptosis 22, 1013–1024.

Makino, A., Scott, B.T., and Dillmann, W.H. (2010). Mitochondrial fragmentation and superoxide anion production in coronary endothelial cells from a mouse model of type 1 diabetes. Diabetologia 53, 1783–1794.

Manoharan, S., Guillen, G.M., Abiramasundari, R.S., Ess, M.M., Akbar, M., and Akbar, M.D. (2016). The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a mini review. OxiMed. Cell. Med. Longev. 2016, 8950978.

Minamino, T., Miyachi, H., Yoshida, T., Ishida, Y., Yoshida, H., and Komuro, I. (2002). Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105, 1541–1544.

Mugoni, V., Camporeale, A., and Santoro, M.F. (2014). Analysis of oxidative stress in zebrafish embryos. J. Vis. Exp. e51328.

Oakley, R., and Tharakan, B. (2014). Vascular hyperpermeability and aging. Aging Dis. 5, 114–125.

Ong, S.B., Subrayan, S., Lim, S.Y., Yellon, D.M., Davidson, S.M., and Hausenloy, D.J. (2010). Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 121, 2012–2022.

Ota, H., Eto, M., Kano, M.R., Ogawa, S., Iijima, K., Akishita, M., and Ouchi, Y. (2008). Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 1634–1639.

Panth, N., Paudel, K.R., and Parajuli, K. (2016). Reactive oxygen species: a key hallmark of cardiovascular disease. Adv. Med. 2016, 9152732.

Paradkar, P.N., Zumbrennen, K.B., Paw, B.H., Ward, D.M., and Kaplan, J. (2009). Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol. Cell. Biol. 29, 1007–1016.

Passos, J.F., Saretzki, G., Ahmed, S., Nelson, G., Richter, T., Peters, H., Wappler, I., Bircket, M.J., Harold, G., Schaeubel, K., et al. (2007). Mitochondrial dysfunction accounts for the stastical heterogeneity in telomere-dependent senescence. PLoS Biol. 5, e110.

Price, J.S., Waters, J.G., Darrah, C., Pennington, C., Edwards, D.R., Donell, S.T., and Clark, I.M. (2002). The role of chondrocyte senescence in osteoarthritis. Aging Cell 1, 57–65.

Quintero, M., Colombo, S.L., Godfrey, A., and Moncada, S. (2006). Mitochondria as signaling organelles in the vascular endothelium. Proc. Natl. Acad. Sci. U S A 103, 5379–5384.

Raimondi, C. (2016). Neuropilin-1 enforces extracellular matrix signaling via ABL1 to promote angiogenesis. Biochem. Soc. Trans. 42, 1429–1434.

Raimondi, C., Brash, J.T., Fantin, A., and Ruhberg, C. (2016). NR1F1 function and targeting in neurovascular development and eye disease. Prog. Retin. Eye Res. 52, 64–83.

Raimondi, C., Fantin, A., Lampropoulou, A., Dent, L., Chik, A., and Ruhberg, C. (2014). Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. J. Exp. Med. 211, 1167–1183.

Raimondi, C., Fantin, A., and Ruhberg, C. (2015). Imatinib may be ABL to improve anti-angiogenic therapy. Mol. Cell. Oncol. 2, e980034.

Rajendran, P., Rengarajan, T., Thangavel, J., Nishigaki, Y., Sakhi, K., Sethi, G., and Nishigaki, I. (2013). The vascular endothelium and human diseases. Int. J. Biol. Sci. 9, 1057–1069.

Rohlenova, K., Veys, K., Miranda-Santos, I., De Bock, K., and Carmeliet, P. (2017). Endothelial cell metabolism in health and disease. Trends Cell. Biol. 28, 224–236.

Roth, L., Prahs, I., Rudkeschel, T., Savant, S., Westrom, S., Fantin, A., Riedel, M., Herout, M., Ruhberg, C., and Augustin, H.G. (2016). Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci. Signal. 9, rs42.
Scaduto, R.C., Jr., and Grotyohann, L.W. (1999). Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys. J. 76, 469–477.

Schoors, S., Bruning, U., Missiaen, R., Queiroz, K.C., Borgers, G., Elia, I., Zecchin, A., Cantelmo, A.R., Christen, S., Goveia, J., et al. (2015). Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520, 192–197.

Sena, C.M., Pereira, A.M., and Seica, R. (2013). Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim. Biophys. Acta 1832, 2216–2231.

Shay, J.W., and Wright, W.E. (2005). Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 26, 867–874.

Shenouda, S.M., Widlansky, M.E., Chen, K., Xu, G., Holbrook, M., Tabit, C.E., Hamburg, N.M., Frame, A.A., Caiano, T.L., Kluge, M.A., et al. (2011). Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 124, 444–453.

Silva-Gomes, S., Santos, A.G., Caldas, C., Silva, C.M., Neves, J.W., Lopes, J., Carneiro, F., Rodrigues, P.N., and Duarte, T.L. (2014). Transcription factor NRF2 protects mice against dietary iron-induced liver injury by preventing hepatocytic cell death. J. Hepatol. 60, 354–361.

Song, Z., Wang, Y., Xie, L., Zang, X., and Yin, H. (2008). Expression of senescence-related genes in human corneal endothelial cells. Mol. Vis. 14, 161–170.

Stokes, M.P., Farnsworth, C.L., Moritz, A., Silva, J.C., Jia, X., Lee, K.A., Guo, A., Polakiewicz, R.D., and Comb, M.J. (2012). PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS. Mol. Cell. Proteomics 11, 187–201.

Sweeney, M.D., Sagare, A.P., and Zlokovic, B.V. (2018). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133–150.

Tsuj, T., Aoshiba, K., and Nagai, A. (2010). Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease. Respiration 80, 59–70.

Turrens, J.F. (2003). Mitochondrial formation of reactive oxygen species. J. Physiol. 552, 335–344.

van Deursen, J.M. (2014). The role of senescent cells in ageing. Nature 509, 439–446.

Vasile, E., Tomita, Y., Brown, L.F., Kocher, O., and Dvorak, H.F. (2001). Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 15, 458–466.

Wang, J., Wang, S., Li, M., Wu, D., Liu, F., Yang, R., Ji, S., Ji, A., and Li, Y. (2015). The neuropilin-1 inhibitor, ATWLPPR peptide, prevents experimental diabetes-induced retinal injury by preserving vascular integrity and decreasing oxidative stress. PLoS One 10, e0142571.

Wang, L., Dutta, S.K., Kojima, T., Xu, X., Khosravi-Far, R., Ekker, S.C., and Mulkopadhyay, D. (2007). Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS One 2, e1161.

Wang, Y., Nakayama, M., Pitulescu, M.E., Schmidt, T.S., Bochenek, M.L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Luthi, U., et al. (2010). Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483–486.

Warboys, C.M., de Luca, A., Amini, N., Luong, L., Duckles, H., Hsiao, S., White, A., Biswas, S., Khamis, R., Chong, C.K., et al. (2014). Disturbed flow promotes endothelial senescence via a p53-dependent pathway. Arterioscler Thromb. Vasc. Biol. 34, 985–995.

Westerfield, M. (1995). The Zebrafish Book. A Guide for the laboratory Use of zebrafish (Danio rerio) (Zebrafish International Resource Center).

Woo, K.J., Lee, T.J., Park, J.W., and Kwon, T.K. (2006). Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway. Biochem. Biophys. Res. Commun. 343, 8–14.
Supplemental Information

Neuropilin-1 Controls Endothelial Homeostasis by Regulating Mitochondrial Function and Iron-Dependent Oxidative Stress

Theo Issitt, Emy Bosseboeuf, Natasha De Winter, Neil Dufton, Gaia Gestri, Valentina Senatore, Anissa Chikh, Anna M. Randi, and Claudio Raimondi
Supplemental Information:

**Transparent Methods**

*Cell culture and transfection:*

Human microvascular dermal ECs (HDMECs) were cultured in MV2 media with supplements (Promocell, UK). HUVECs were cultured in EGM-2 (Promocell, Germany). Primary MLECs were isolated from mice between 1 and 2 months of age by magnetic-activated cell sorting (MACS) with PECAM (BD, UK) and ICAM2 (BD, UK). MLECs were cultured on 10 µg/ml FN in DMEM-GlutaMAX supplemented with 20% FBS, nonessential amino acids (Life Technologies, UK), and ECGS (Sigma-Aldrich, UK). HDMECs and HUVECs were cultured for up to five passages and transfected with Lipofectamine RNAiMAX transfecting agent (Thermofisher, UK). The following siRNAs were used to transfect HDMECs and HUVECs: SMARTpool siRNA targeting NRP1 (Dharmacon, USA; cat#: L-019484-00-0020); sequence 1: CGAUUAAUGUGGCGAUACU; antisense: AGUAUCGCCACAUUUAGCG; sequence 2: GGACAGAGACUGCAAGUAU; antisense: AUACUUGCAGUCUGUCC; sequence 3: GUAUACGGGUUGCAAGAUAA Antisense: UUAUCUUGCAACCGUAUAC; sequence 4: AAGACUGGAAUCACCAAAAA antisense: UUUAUGGUAGUCAGCUU; SMARTpool siRNA targeting VEGFR2 (Dharmacon, USA; cat# L-003148-00-0010); sequence 1: GGGCAUGUACUGACGAUUA Antisense: UAAUCGUCAGUACAUGCCC; sequence 2: CUACAUUGUUCUUCCGAUA Antisense: UAUCGGAAGAACAAUGUAG; sequence 3: GCGAUGGCCUCUUCUGUAA; Antisense: UUACAGAAGAGGCCAUCGC sequence 4: GGAAACUCUUGCAACGAUA; Antisense: UAGCUUGCAAGAGUUC; SMARTpool siRNA targeting ABCB8 (Dharmacon, USA; cat#: L-007306-02-0010; sequence 1: CAACCGGUGCACGCCGGA; antisense: UCGGCCAUGCAGACCCUGUG; sequence 2: UCACCUUCUUUGACGCCCA; Antisense: UUGCGGUUCCACGAGUGA; sequence 3: AACCGGAAGAGGAGCCGUU; sequence 4: GCAUUGCCUCUUCGUUA; antisense: UCGGCAUGACGACAAUGC; Silencer® negative control siRNA (Life Technology, UK; cat# AM4635). In some experiments, HDMECs were transfected with Hs NRP1 7 FlexiTube siRNA single sequence (Cat. SI02663213) or Hs NRP1 8 FlexiTube siRNA (Cat. SI02663213) from Qiagen, UK. In some experiments, cells were double transfected with both siNRP1 and siABCB8. The amount of siRNA was
maintained identical among the different single and double transfections. In some experiments, ECs were treated with mitoTEMPO 10µM (Sigma Aldrich, UK) or Deferoxamine (100 µM) (Sigma Aldrich, UK) for 24 hours in growth media.

**Animals:**

All animal procedures were performed in accordance with institutional and UK Home Office guidelines. Lung endothelial cells were isolated from C57/Bl6 wild type mice (Charles River Laboratories, UK), and mice carrying two floxed conditional null Nrp1 alleles (Nrp1\(^{fl/fl}\)) combined with Pdgfb-iCre\(_{ERT2}\)-Egfp with codon-improved Cre on a C57/Bl6 background (Gu et al., 2003; Raimondi et al., 2014). Aortas were isolated from B6.129 (SJL)-Nrp1\(^{tm2Ddg}\)/J(Gu et al., 2003) (Charles River Laboratories, UK) combined with C57/Bl6 Cdh5(PAC)-iCre\(_{ERT2}\) with codon-improved Cre (Wang et al., 2010). Zebrafish lines Tg(fli1a:egfp)y5 (Lawson and Weinstein, 2002) and nrp1a sa1485 (generated by the Sanger Centre Zebrafish Mutation Project) were maintained and bred according to standard procedures (Westerfield, 1995). Ethical approval for zebrafish experiments was obtained from the Home Office UK under the Animal Scientific Procedures Act 1986.

For tamoxifen-induction of CRE-mediated recombination, 0.5 mg of tamoxifen (Sigma Aldrich, UK) dissolved in peanut oil to 2 mg/ml was administered via intraperitoneal injection at the indicated times to generate Nrp1\(^{ECKO}\) and Nrp1\(^{WT}\) mice.

**Gene expression:**

mRNA was collected using the RNAeasy system (Qiagen, UK) and cDNA was prepared using Superscript III reverse transcription (Life Technology, UK) and amplified with SYBR Green PCR reagent (Quantabio, USA) and the following oligonucleotide primers:

- NRP1, 5’-GAAAAATCGAATGCTGAT-3’ and 5’-AATCCGGGGGACTTTATCAC-3’
- VEGFR2, 5’-AGATGGTGTAAACCCGGAGTG-3’ and 5’-
- ACATGTACAGGTTCGGAGGT-3’
- ABCB8, 5’-AGTACTCTGATGGCTACCGC-3’ and 5’-CAGAGGTGGGGATGCTTACT-3’
- HO-1, 5’-TTCTATCACCCTTCCCCAACA-3’ and 5’-CCTCTTCACCTTCCCCCAACA-3’
- SOD1, 5’-GGATGAAGAGAGGCATGTTGGAGAC-3’ and 5’-GTCTTTGTACTTTCTTCATTTCCACC-3’
- SOD2, 5’-AGCAGTGGAAATAGGCTGT-3’ and 5’-CAAAGGGGAGTTGCTGGAAG-3’
TRF1, 5'-CAGTTGGAGTGCTGGAGACT-3' and 5'-AGCGTATACACAGTGGGCT-3'; Ferroportin-1, 5'-TACTTGTGCCTCCCAGATGG-3' and 5'-ATGGAACCACCGAGATCCCTTG-3'; Mitoferrin-1, 5'-CCAGATCCAAAGCCAGTCTCCAGAT-3' and 5'-CCATACTCCCAGCTTCCCG-3'; Mitoferrin-2, 5'-CCACGCTTTTATTTTGCT-3' and 5'-TCCTCTGTGGACCACCTCC-3'; GAPDH, 5'-CAAGGTCATCCATGCAACTTGTG-3' and 5'-GGGCCATCCACAGTCTTCTCAG-3'

**Immunoblotting:**

Cells were lysed in 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 50 mM Glycerophosphate (Sigma-Aldrich, UK), 1% Tween-20, 0.2% Igepal (Sigma-Aldrich, UK) in the presence of protease inhibitor cocktail 2 (Sigma-Aldrich, UK) and phosphatase inhibitor cocktail (Sigma-Aldrich, UK). 35µg of protein lysate were resuspended in Laemmli buffer, denatured for 5 minutes at 95°C, separated by SDS-PAGE and transferred to nitrocellulose membrane (Whatman, USA). Nitrocellulose membranes were immunoblotted with the following primary antibodies: mouse anti-GAPDH (Abcam, UK); rabbit anti-NRP1, rabbit anti-VEGFR2 (Cell Signaling Technology, USA); rabbit anti-TOM20, rabbit anti-MFN1, rabbit anti-MFN2 (Proteintech, USA), mouse monoclonal anti-KDEL (BD, UK), mouse anti-EEA1 (BD, UK), rabbit anti-ABCB8 (Sigma Aldrich, UK), mouse anti-Transferrin-1 (HTF-14) (Novus Biologicals, UK), goat anti-CDH5, rabbit anti-human p16 (C-20) and rabbit anti-mouse p16 (M-156) (Santa Cruz Biotechnology, USA); rabbit anti-SIRT1, rabbit anti-cyclin D1, rabbit anti-cyclin D2, (Cell Signaling Technology, USA). HRP-conjugated secondary antibodies were used for chemiluminescence detection with ECL prime (Amersham, UK) and protein levels were quantified by densitometry with ImageJ (NIH, Bethesda US).

**Immunoprecipitation:**

ECs were lysed in 50 mM Tris, pH 8.0, 50 mM KCl, 1% (vol/vol) NP-40 in the presence of protease inhibitor cocktail 2 and phosphatase inhibitor cocktail. 1mg of protein was incubated with 3µg goat anti-NRP1 (Raimondi et al., 2014), or control goat or rabbit IgG (Santa Cruz Biotechnology) and then with 30 µl protein G Sepharose 4 fast flow (GE Healthcare, UK) at 4°C. Beads were washed three times with lysis buffer on a rotating wheel at 4°C for 5 minutes and resuspended in 50µl Laemmli sample buffer for SDS-PAGE and immunoblotting.
Mitochondrial Fractionation:

Mitochondrial fractionation was performed using the Qproteome Mitochondria Isolation Kit (Qiagen, UK). Briefly, 12 million of HDMECs were suspended in Lysis Buffer, centrifuged and the resulting pellet was resuspended in Disruption Buffer. The pellet was disrupted by repeatedly passing through a 23G blunt ended needle to ensure complete cell disruption and recentrifuged to pellet nuclei, cell debris, and unbroken cells. Then, the supernatant containing mitochondria and the microsomal fraction was centrifuged to pellet mitochondria. Mitochondria were washed and resuspended in Mitochondria Storage Buffer and carefully pipetted on top of layers of a gradient purification buffer which allowed the mitochondria to form a band. The band was removed, and the high-purity mitochondria lysed and analysed by immunoblotting for NRP1, GAPDH, ABCB8, TOM20, KDEL and EEA1. Mouse monoclonal [10C3] anti-KDEL (BD, UK) and mouse monoclonal clone 14 anti-EEA1 (BD, UK) were used for immunoblotting analysis.

Immunofluorescence:

For experiments with fixed samples, HDMECs were fixed in 4% formaldehyde in PBS for 10 minutes, permeabilised in 0.25% Triton X-100 in PBS for 3 minutes, blocked for 30 minutes in 0.1%BSA in PBS and incubated overnight with the following primary antibodies: Rabbit anti-TOM20, (Proteintech, UK), rabbit anti-ABCB8 (Sigma, UK), mouse anti-NRP1 (R&D Systems, UK), mouse anti-Transferrin-1 (Santa Cruz Biotechnology, US). The following conjugated secondary antibodies were used: Alexa-488 conjugated goat anti-rabbit/anti-mouse or Alexa-594 anti-rabbit/anti-mouse secondary antibodies (ThermoFisher Scientific, UK) and DAPI (Sigma-Aldrich, UK). Images were acquired with a plan apochromat 63X 1.4 NA oil objective on an LSM780 confocal microscope (Zeiss, Germany). Confocal z-stacks were acquired with an LSM780 laser scanning confocal microscopes (Zeiss, Germany). Maximal intensity projections were generated with ImageJ (NIH, Bethesda, USA) and normalized to DAPI pixel intensity. Mitochondrial areas and volumes per cell were calculated by generating a 3D-rendered surface based on Mitotracker staining with IMARIS (Bitplane, AG). For colocalization analysis, z-stacks acquired with an LSM780 laser scanning confocal microscopes (Zeiss) were deconvoluted with Huygens Deconvolution software (Scientific Volume Imaging B.V., The Netherlands).
and analysed for colocalization using the intensity correlation analysis plug-in for ImageJ (NIH, Bethesda, USA); 3D projection was generated and analysed with Volocity (PerkinElmer, UK).

**Whole-mount aorta:**

Aortas were obtained by dissection from \( \text{Nrp}^\text{WT} \) or \( \text{Nrp}^\text{ECKO} \) mice, fixed in 4% paraformaldehyde for 5 minutes, permeabilised with 1:1 Methanol:Acetone for 5 minutes and blocked with 3% BSA in PBS-T for 1 hour. Samples were incubated overnight in 3% BSA in PBS-T with goat anti-NRP1 (R&D, UK) and rabbit anti-PECAM (Invitrogen, UK) or with goat anti-ABCB8 (Santa Cruz Biotechnology, US) and rabbit anti-PECAM. Primary antibodies were detected with Alexa-488 or Alexa-555 anti-rabbit/anti-goat secondary (ThermoFisher Scientific, UK). Nuclei were counterstained with DAPI. Z-projection were generated with ImageJ (NIH, Bethesda, USA) and z-stack pixel intensity was analysed with ImageJ (NIH, Bethesda, USA).

**Mitosox live-staining:**

ECs were incubated with 5µM Mitosox (Sigma-Aldrich, UK) and 5µg/ml Hoescht 33342 (Sigma-Aldrich, UK) in HBSS with Ca\(^{2+}\) and Mg\(^{2+}\) (Life Technology, UK) for 8 minutes, washed three times with HBSS with Ca\(^{2+}\) and Mg\(^{2+}\) before imaging with an LSM780 confocal microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, Germany). In some cases, cells were treated with 100µM Deferoxamine (Sigma-Aldrich, UK) for 24 hours before imaging. Mitosox and Hoescht 33342 integrated density was determined with ImageJ (NIH, Bethesda, USA).

**CellROX:**

Zebrafish embryos were raised at 28.5°C in fish water and to prevent pigment formation, 0.003% phenylthiourea (PTU, Sigma) was added to the fish water at 10hpf. 3dpf embryos were incubated in the dark with 2.5 µM CellROX (Invitrogen) in 10% DMSO for 45 minutes. Followed CellROX staining, embryos were anaesthetised with MS-222 (Sigma-Aldrich, UK), immobilised in 1.2% low melting point agarose (Sigma-Aldrich, UK) and imaged from a lateral perspective using a Leica SP8 confocal microscope. During confocal analysis, we excluded territories containing pigment cells as, even after PTU treatment, showed autofluorescence that could not be
distinguished from CellROX labelling. CellROX staining in the vasculature was quantified with IMARIS (Bitplane, AG) by applying a virtual mask to the z-stacks acquired by high-resolution confocal microscopy to isolate GFP-positive vascular territories. Thus, cellROX signal within the vasculature was quantified and normalized to GFP signal.

Tetramethylrhodamine methyl ester (TMRM) live-staining:

ECs were incubated with 100nM TMRM for 30 minutes in growth MV2 media (HDMECs) or EGM2 (HUVECs), washed three times with HBSS with Ca2+ and Mg2+ before imaging with an LSM 510 confocal microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, Germany). In some cases, cells were nuclear counterstained using DRAQ5 (ThermoFisher, UK) or treated with 100µM Deferoxamine (Sigma-Aldrich, UK) for 24 hours before imaging. TMRM integrated density was determined with ImageJ (NIH, Bethesda, USA) and normalized to the number of cells. In some experiments, ECs were incubated with 100nM TMRM and 300nM Mitotracker Deep Red to simultaneously visualise mitochondria and mitochondrial membrane potential and live-imaged with an LSM 510 confocal microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, Germany). TMRM and Mitotracker integrated density was determined with ImageJ (NIH, Bethesda, USA) and expressed as TMRM/Mitotracker ratio.

Mitotracker staining:

ECs were incubated with serum-free MV2 media (Promocell, Germany) containing 500nM MitoTracker™ Orange (ThermoFisher, UK) for 30 minutes. Cells were washed three times in HBSS Ca2+ and Mg2+ (Life Technology, UK), fixed in 4% PFA for 10 minutes at RT, nuclear counterstained with DAPI and imaged with an LSM710 confocal microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, Germany).

Mito-FerroGreen live-staining:

ECs were washed three times with HBSS supplemented with Ca2+ and Mg2+ and incubated for 30 minutes with 5µM Mito-FerroGreen and 300nM Mitotracker Deep Red. Then, ECs were washed three times with HBSS supplemented with Ca2+ and Mg2+ and live-imaged with a widefield microscope with a plan apochromat 40X air
objective (Zeiss, Germany) or with an LSM780 confocal microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, Germany). Mito-FerroGreen pixels were determined with ImageJ (NIH, Bethesda, USA) and normalized to the number of cells.

**Intracellular Iron assay:**

Intracellular iron of HDMEC transfected with si-control or si-NRP1 for 72 hours was measured using the colourimetric Iron Assay Kit (Catalog #K390-100 Biovision, US) following the manufacturer's instructions. The kit measures Ferrous and Ferric ion in tissues or cell samples (Bai et al., 2017). In the assay, ferric carrier proteins will dissociate ferric iron into solution in the presence of acid buffer. After reduction to the ferrous form (Fe^{2+}), iron reacts with Ferene-S to produce a stable coloured complex with absorbance at 593 nm.

**Proximity ligation assay:**

HDMECs were grown on gelatinised coverslips in 8-well chambers (Labtek, Sigma-Aldrich, UK). Cells were fixed with 4% paraformaldehyde for 15 minutes prior to blocking with 3% BSA for 1 h. PLA was performed following the manufacturer's instructions (Duolink, Sigma-Aldrich, UK) using primary mouse anti-NRP1 (antibody R&D Systems, UK), goat anti-ABCB8 (Santa Cruz Biotechnology, USA), rabbit anti-TOM20 (Proteintech, UK) and mouse anti-phosphoserine antibody (clone PSR-45, P5747, Sigma-Aldrich, UK). As control isotype mouse IgG (Santa Cruz Biotechnology, USA) and goat IgG (Santa Cruz Biotechnology, USA) were respectively used in combination with goat anti-ABCB8 or mouse anti-NRP1 or rabbit anti-TOM20. Cells were mounted with Vectashield (Vector Laboratories, USA) and imaged with an LSM780 confocal microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, Germany). PLA signal was analysed with the Analyze Particle function of ImageJ (NIH, Bethesda, USA).

**BrdU and apoptosis analysis by FACS:**

HDMECs were incubated with 10μM BrdU (Sigma) for 30 minutes, washed with PBS and harvested 48 hours after BrdU incorporation. Cells were then washed in PBS, trypsinized, pelleted and resuspended in ice-cold 70% ethanol for 30 minutes at 4°C. Fixed samples were then pelleted, resuspended in 2N HCl at room temperature for 30 minutes. Cells were washed in PBS supplemented with 0.1% BSA
and 0.2% Tween-20, pH 7.4, incubated with 2μl anti-BrdU (Becton Dickinson) at room temperature for 20 minutes, then washed in PBS-Tween and incubated with secondary antibody conjugated with Alexa (Molecular Probes) for 20 minutes at room temperature. Samples were washed in PBS, incubated with 50 μl RNase (100 μg/ml, Sigma) at 37°C for 15 minutes and then incubated with Propidium iodide (50 μg/ml, Sigma). Apoptosis was assessed by flow cytometry by using annexin V and propidium iodide staining. Cells were washed in PBS, trypsinized, pelleted and resuspended in 400 μl of binding buffer (Becton Dickinson, San Jose, CA); samples were incubated with 2 μl of annexin-V–FITC (Becton Dickinson) for 15 minutes at room temperature, then propidium iodide (5 μg/ml) was added to the sample.

SA-β-gal assay:

SA-β-gal activity was identified with the Senescence Cells Histochemical Staining Kit (catalogue number CS0030; Sigma-Aldrich, UK). Briefly, ECs were fixed for 6 minutes in 1X fixation buffer (2% formaldehyde, 0.2% glutaraldehyde, 7.0 mM Na2HPO4, 1.5 mM KH2PO4, 0.13 M NaCl, and 2.68 mM KCl), washed twice with PBS and then incubated for 16 hours at 37°C with SA-β-gal staining solution comprised of 5-bromo-4-chloro-3-indoyl β-D-galactopyranoside (X-Gal; 1mg/ml, diluted from a 40 mg/ml stock solution in N,N-dimethylformamide), potassium ferrocyanide (5 mM) and potassium ferricyanide (5 mM) in PBS (pH 6.0.) Following incubation, cells were washed three times with PBS and viewed under phase contrast using a Nikon Eclipse TS100 microscope with a 10x objective (N.A. 0.3, W.D. 16.0 mm). Senescent ECs were identified by the presence of obvious blue reaction product. For each sample, the average percentage of SA-β-gal positive cells in each of three fields of view (0.785 mm2) was calculated as the value for that sample.

PTMScan:

Samples were analyzed using the PTMScan method as previously described (Stokes et al., 2012). Cellular extracts were prepared in urea lysis buffer, sonicated, centrifuged, reduced with DTT, and alkylated with iodoacetamide. Equal amounts of total protein for each sample was digested with trypsin and purified over C18 columns for enrichment with the Phosphotyrosine pY-1000 antibody (#8954) or Phospho-Enrichment IMAC Fe-NTA Magnetic Beads (#20432). Enriched peptides were purified over C18 STAGE tips. Replicate injections of each sample were run non-
sequentially on the instrument. Peptides were eluted using a 90- or 150-minute linear gradient of acetonitrile in 0.125% formic acid delivered at 280 nL/min. Tandem mass spectra were collected in a data-dependent manner with an Orbitrap Velos or Elite Hybrid Ion Trap-Orbitrap Mass Spectrometer running XCalibur 2.0.7 SP1 using a top-twenty MS/MS method, a dynamic repeat count of one, and a repeat duration of 30 seconds. Real-time recalibration of mass error was performed using lock mass with a singly charged polysiloxane ion m/z = 371.101237. MS/MS spectra were evaluated using SEQUEST and the GFY-Core platform. Files were searched against the NCBI homo sapiens FASTA database. A mass accuracy of +/-50 ppm was used for precursor ions and 1.0 Da for product ions. Enzyme specificity was limited to trypsin, with at least one tryptic (K- or R-containing) terminus required per peptide and up to four mis-cleavages allowed. Cysteine carboxamidomethylation was specified as a static modification, oxidation of methionine and phosphorylation on serine, threonine, or tyrosine residues were allowed as variable modifications. Reverse decoy databases were included for all searches to estimate false discovery rates and filtered using a 5% FDR in Core. Peptides were also manually filtered using a -/+ 5ppm mass error range and presence of at least one phosphorylated residue on each peptide. All quantitative results were generated using Progenesis V4.1 (Waters Corporation) to extract the integrated peak area of the corresponding peptide assignments. The accuracy of quantitative data was ensured by manual review in Progenesis or in the ion chromatogram files. A 2.5-fold cutoff was used to denote changes between samples and analytical % CV values were calculated for each peptide to determine reproducibility across runs. A limited version of the raw dataset containing only PTMscan data of mitochondria-associated proteins has been made available to readers due to intellectual property concerns.

Statistical analyses:

Statistical analyses were performed with GraphPad (Prism) or Office Excel (Microsoft); data obtained from cell lines were analysed with a two-tailed, paired t-test; data obtained from the zebrafish experiments were analysed with a one-way ANOVA statistical test; data obtained from mouse experiments were analysed with a two-way ANOVA statistical test.
Figure S1 – Related to Figure 1 and Figure 3: A) HDMECs si-control or si-NRP1 immunostained for NRP1, TOM20 and counterstained with DAPI (n=3). Arrows indicate NRP1 staining at the plasma membrane and in filopodia; Scale bars: 20µm. B) Representative immunoblot for NRP1 of HDMECs si-NRP1 or si-control 72 hours with GAPDH used as loading control; (n≥5). C) High magnification orthogonal view of NRP1 and TOM20 double-stained HDMEC showing colocalization (arrows) of NRP1 and TOM20 along X and Y axes; scale bars 3µm and 5µm. C’) High magnification of the area indicated in panel C, showing colocalization of TOM20 and NRP1 within three-dimensional structures. D) Colocalization analysis of single z-planes extracted from the z-stack shown in panel C and in Figure 1A; Scale bar 15µm. E) PLA for TOM20 and NRP1 or TOM20 and IgG isotype of HDMECs si-control and si-NRP1 analysed using a confocal microscope; Scale bars: 20µm. F) PLA signal (grey) per cells (mean ± SEM) was measured in a minimum of 92 cells from 2 independent experiments. G) Fractions isolated with Qproteome mitochondria isolation kit from HDMECs were immunoblotted for the indicated antibodies (n=3). H) Aortas of Nrp1<sup>fl/fl</sup> (Nrp1<sup>WT</sup>) injected daily with tamoxifen for 5 days and sacrificed after 1 month from injections stained with secondary only as negative control; bar 30µm. *, P < 0.05, Student’s t-test.
Figure S2, related to Figure 2 and Figure 3:

A) HDMECs incubated with TMRM 100nM and counterstained with DRAQ5 (blue) were treated or left untreated with 10µM CCCP; n=2; Scale bars: 20µm. B) HUVECs siNRP1 or si-control were incubated with 100nM TMRM and 300nM Mitotracker Deep Red FM and live-imaged with a confocal microscope. C) TMRM and Mitotracker Deep FM integrated density was calculated, and the ratio visualised in the graph (mean ± SEM; n=4). D) Representative immunoblotting for NRP1 in lysates from HDMECs transfected with si-control, anti-NRP1 single sequence 7 or single sequence 8 siRNAs. GAPDH was used as loading control (n=3). E) HDMECs transfected with siNRP1 single sequence 7 or single sequence 8 or si-control were incubated with 100nM TMRM and 300nM Mitotracker Deep Red FM and live-imaged with a confocal microscope. F) TMRM and Mitotracker Deep Red FM integrated density was calculated, and the ratio visualised in the graph (mean ± SEM; n=3). G) Representative immunoblots for NRP1, HO-1 and GAPDH in HDMECs si-NRP1 or si-control. H) Quantification of expression levels as pixel intensity relative to GAPDH pixel intensity; n=3. I) Heat map showing data from PTMscan of phosphorylated mitochondrial proteins in HDMECs transfected with si-control or si-NRP1 for 72 hours. Data are expressed as fold change of si-control; n=2. J) HDMECs were co-stained for ABCB8 (green) and TOM20 (red) with DAPI (blue) used as counterstaining. Right panels show a bi-parametric correlative histogram; Scale bars: 20µm. *, P < 0.05, Student’s t-test.
Figure S3 – Related to Figure 4 and Figure 5: A) Quantification of Transferrin-1 (TFR1) and Ferroportin-1 mRNA by RT-qPCR in HDMECs transfected for 72 hours with si-NRP1 or si-control. Transcripts levels were expressed as fold change of si-control (mean ± SEM; n=3). B) Representative immunoblot for NRP1 and Transferrin-1 (TFR1) of lysates of HDMECs si-control or siNRP1. GAPDH was used as equal loading control; n=3. C) Quantification of Mitoferrin-1 and Mitoferrin-2 mRNA by RT-qPCR in HDMECs transfected for 72 hours with si-NRP1 or si-control. Transcripts levels were expressed as fold change of si-control (mean ± SEM; n=3). D) HUVECs treated with Deferoxamine 100µM for 24 hours after 48 hours from transfection with si-NRP1 or si-control were incubated with 100nM TMRM (grey) and live-imaged with a confocal microscope; Scale bars: 20µm. E) Integrated density of the TMRM signal was quantified, normalized to cell number, and expressed as percentage relative to si-control (mean ± SEM; n=3). F) Representative immunoblotting for ABCB8 in HDMECs si-ABCB8 or si-control (n=2). G) HUVECs treated with Deferoxamine 100µM for 24 hours after 48 hours from transfection with si-ABCB8 or si-control were incubated with 100nM TMRM (grey) and live-imaged with a confocal microscope; Scale bars: 20µm. H) Integrated density of the TMRM signal was quantified, normalized to cell number and expressed as percentage relative to si-control (mean ± SEM; n=3). *, P < 0.05; n.s. = not significant; Student’s t-test.